Slides
Page 1
GrupoFleury Investor Relations YEARS FUTURE BUILT ON SCIENCE AND TRUST 2Q26 Earnings August 07 , 2026 PARDINI LABCLASS Hermes Pardini SÃO LUCAS ANALISE CLINICAL
Page 2
2 This presentation may contain information about future events. Such information is not just historical facts, but would reflect the wishes and expectations of the company's management. The words "believe", "expect", "plan", "anticipate", "estimate", "project", "aim" and the like are intended to identify statements that necessarily involve known and unknown risks. Known risks include uncertainties, which are not limited to the impact of price and service competitiveness, market acceptance of services, company and competitor service transactions, regulatory approval, currency fluctuation, changes in the mix of services offered and other risks. described in the company's reports. Additional unaudited or audited information contained herein reflects the interpretation of the Company's Management on information derived from its financial statements and their respective adjustments, which were prepared in accordance with market practices and for the exclusive purpose of a more detailed and specific analysis. of the Company's results. Therefore, such considerations and additional data must also be analyzed and interpreted independently by shareholders and market agents, who must make their own analyzes and conclusions on the information disclosed herein. No data or interpretative analysis carried out by the Company's Management should be treated as a guarantee of performance or future results and are merely illustrative of the Company's Management's view of its results. The Company's Management is not responsible for the compliance and accuracy of the information discussed in this report. Such information should be considered for informational purposes only and not as a substitute for analyzing our audited or audited consolidated financial statements for the purpose of an investment decision in our shares, or for any other purpose. This presentation is up to date and Grupo Fleury is not obliged to update it in light of new information and/or future events. All comparisons made are relative to the same period of the previous year, unless otherwise specified. DISCLAIMER Disclaimer
Page 3
Agenda Investor Relations Overview Lab-to-Lab Financial Highlights
Page 4
FOTOGRAFIA DA OPERAÇÃO Colar sobre este quadrado Investor Relations Overview Felippe Mattoso (Rio de Janeiro – RJ)
Page 5
5 OVERVIEW Integration of the patient’s journey Note: Non-exhaustive brand list Check-ups Vaccines Genomics Telemedicine Appointments Infusion Orthopedics Ophthalmology Fertility Ambulatorial Surgical Center Prevention Primary Care Secondary Care Tertiary Care Diagnostics Tech Platforms Joint Ventures Genomics: + Oncology: + + Other Initiatives A l b e r t E i n s t e i n I s r a e l i H o s p i t a l T h e P o r t u g u e s e B e n e f i- c i e n c yo f S a o P a u l o B2C + B2B
Page 6
6 OVERVIEW Business Units strengthen the integration of the patient journey * Equivalent to 10,9% of B2C or 71 patient service centers 34 Regional Brands 583 Patient Service Centers National wide reach 9.300+ L2L Clients 9 Brands 35+ Hospital Clients 5 Specialties 10 Brands 29 Units Telemedicine Others B2C Diagnostic Medicine B2B Diagnostic Medicine New Links 2Q26 LTM Revenues 70% - PSC: 62% - Mobile: 8%* 21% 9% Business Units
Page 7
7 OVERVIEW Grupo Fleury has diversified its revenue sources over time B2C (70%) 13 14 15 16 17 18 19 20 21 22 23P 24 25 New Links (20-2Q26 LTM) R$ 0,8 m 72,7% aa B2B R$ 2,0 b 15,6% aa Regional R$ 1,1 b 16,7% aa MG R$ 0,8 b 2,6x aa RJ R$ 1,1 b 7,1% aa 12 Fleury Brand R$ 2,4 b 9,1% aa 1,7 1,9 1,9 2,1 2,3 2,6 2,9 3,1 3,2 4,2 4,8 7,7 8,3 9,0 2Q26 LTM 9,5 SP R$ 1,4 b 20,1% aa B2C R$ 6,7 b 12,3% aa B2C R$ 1,4 b B2C 83% 7% 8% 8% 8% 9% 25% 43% 12 13 14 15 16 16% 16% 10% 50% 17 18 19 20 21 17% 23P 24 25 New Links B2B Regional MG RJ SP Fleury Brand 2Q26 LTM 25% 15% 11% 11% 21% 22 R$ Bi 100% CAGR 12-2Q26 LTM 13,7% aa
Page 8
FOTOGRAFIA DA OPERAÇÃO Colar sobre este quadrado Investor Relations Lab-to-Lab Lab-to-Lab (Air Logistics)
Page 9
9 LAB -TO -LAB Lab-to-Lab fosters access to quality, fast, and efficient healthcare, as well as the growth of thousands of independent laboratories +270cars +160 motorcycles Waterway transportation in more remote regions Air transportation with commercial companies Logistical complexity: +430 routes Geographical reach: +80% population +2.200 cities served ~93.000 km traveled daily +9.300 clients 16 Technical Areas +9.000 exams in portfolio
Page 10
FOTOGRAFIA DA OPERAÇÃO Colar sobre este quadrado Investor Relations Financial Highlights Hermes Pardini (Belo Horizonte – BH)
Page 11
11 FINANCIAL HIGHLIGHTS 2Q26 Highlights Consistency in Delivering Results Gross Revenue of R$ 2,5 billion • 14,4% growth • B2C: +15,0% (+11,6% organic) • Fleury Brand: +12,0% • Others SP: +27,7% (+12,9% organic) • RJ: +8,9% • MG: +19,2% (+14,3% organic) • Regional: +10,2% • B2B: +12,2% • New Links: +15,9% EBITDA of R$ 612,9 million • 15,2% growth • Margin of 26,5% (18 bps above 2Q25) Net Income of R$ 221,9 million • 45,7% growth • Margin of 9,6% (205 bps above 2Q25) Increasing ROIC • Reached 17,8%* (380 bps above 2Q23) * ROIC ex-Hermes Pardini deal surplus
Page 12
12 FINANCIAL HIGHLIGHTS Gross Revenue R$ Million 2Q25 2Q26 2.197,8 2.514,6 +14,4% R$ 2,5 bi (+14,4%; +12,1% organic) • B2C: +15,0% (+11,6% organic) • B2B: +12,2% • New Links: +15,9% 6M25 6M26 4.386,2 4.924,8 +12,3%
Page 13
13 B2C 11,6% 12,9% 14,3% 3,4% 14,8% PSCs* Fleury Others SP RJ MG Regional +15,0% +12,0% +27,7% +8,9% +19,2% +10,2% 4,9% R$ 1,8 bi (+15,0%; +11,6% organic) • Good organic performance in BH, ES, GO, PR, RJ, RS and SP • Inorganic effect of Confiance and LSL in SP, and Hemolab in MG FINANCIAL HIGHLIGHTS Inorganic: LTM Acquisitions * Patient Service Center 11,7% 13,5% 14,6% 3,3% 14,4% +15,0% +12,0% +27,9% +9,0% +19,4% +9,6% 4,8% 2Q26 x 2Q25 6M26 x 6M25
Page 14
14 B2B R$ Million FINANCIAL HIGHLIGHTS 6M25 6M26 966,0 1.051,6 +8,9% R$ 545,1 m (+12,2%) • Lab-to-Lab: Share-of- wallet gains in common tests • Hospitals: Benefited from Influenza outbreak during the quarter 2Q25 2Q26 485,9 545,1 +12,2%
Page 15
15 2Q25 2Q26 174,1 201,8 +15,9% FINANCIAL HIGHLIGHTS R$ 201,8 m (+15,9%) • Strong performance across all businesses, especially in non- oncology drug infusions * It includes digital platforms New Links* R$ Million 6M25 6M26 396,6 395,8 -0,2%
Page 16
16 Gross Profit R$ Million; % Net Revenue 26,1% 27,8% 2Q25 2Q26 528,0 644,1 +22,0% R$ 644,1 m (+22,0%) • Margin of 27,8% (+173 bps) • Depreciation and Amortization (+131 bps; change in Capex profile due to lower IT and Digital investment) • Personnel and Medical Services (+113 bps; fixed cost dilution due to volume growth) • Occupancy and Utilities (-64 bps; increase in variable costs due to higher volume of exams and clients) FINANCIAL HIGHLIGHTS 27,2% 28,0% 6M25 6M26 1.100,1 1.272,2 +15,6%
Page 17
17 Operational Expenses R$ Million; % Net Revenue 10,9% 10,9% 2Q25 2Q26 221,1 252,4 +14,2% R$ 252,4 m (+14,2%) • 10,9% of Net Revenue • General and Administrative (-15 bps; expenses control discipline) • Depreciation and Amortization (+36 bps; change in Capex profile due to lower IT and Digital investment) FINANCIAL HIGHLIGHTS 11,4% 11,3% 6M25 6M26 460,0 512,6 +11,4%
Page 18
18 EBITDA R$ Million; % Net Revenue 26,3% 26,5% 2Q25 2Q26 532,1 612,9 +15,2% R$ 612,9 m (+15,2%) • Margin of 26,5% (18 bps above 2Q25) • EBIT increase partially offset by lower D&A FINANCIAL HIGHLIGHTS 26,7% 26,9% 6M25 6M26 1.079,7 1.218,9 +12,9%
Page 19
19 Net Income R$ Million; % Net Revenue 7,5% 9,6% 2Q25 2Q26 152,3 221,9 +45,7% FINANCIAL HIGHLIGHTS R$ 221,9 m (+45,7%) • Margin of 9,6% • ETR of 21,8% 8,2% 9,3% 6M25 6M26 331,6 423,1 +27,6%
Page 20
20 CAPEX R$ Million 86,9 24,0 30,6 2Q25 19,8 12,9 43,0 2Q26 141,5 75,7 -46,5% R$ 75,7 m (-46,5%) • IT/Digital (-77,2%) • Diag. Quip. Renovation and Maintenance (-46,2%) • New PSCs, Offer Exp. In Units and Tec. Areas (+40,6%) • Back to the historical profile characterized by lower IT and digital investment and a greater focus on expanding the offering and capacity of technical areas FINANCIAL HIGHLIGHTS IT/Digital Diag. Equip. Renovation and Maintenance New PSCs, Offer Exp. In Units and Tec. Areas 117,2 40,6 50,5 6M25 38,9 21,5 75,9 6M26 208,3 136,3 -34,6%
Page 21
21 Operational cash Flow R$ Million 2Q25 2Q26 487,1 695,8 +42,9% R$ 695,8 m (+42,9%) • Cash conversion of 100,5% of EBITDA in 2Q26 LTM FINANCIAL HIGHLIGHTS 6M25 6M26 809,4 960,4 +18,7%
Page 22
22 ROIC and Leverage %; R$ Million 1,1x 1,0x 1,1x 2.191 2.320 2Q25 2.267 2.277 1Q26 2.038 2.422 2Q26 4.511 4.543 4.460 Cash Net Debt Leverage Covenant 3,0x FINANCIAL HIGHLIGHTS Leverage • Below the covenant limit 14,0% 14,4% 15,9% 16,1% 16,5% 16,6% 17,0% 17,8% 2Q23 3Q23 14,6% 4Q23 15,3% 1Q24 2Q24 3Q24 16,4% 4Q24 16,9% 1Q25 16,4% 2Q25 3Q25 4Q25 1Q26 2Q26 +380bps ROIC • Gain of 380 bps since 2Q23
Page 23
23 2.038 Cash Jun/26 668 396 1.209 1.127 531 531 3Q26 – 2Q27 3Q27 – 4Q27 2028 2029 2030 2031 Cash Position and Debt Amortization Schedule R$ Million FINANCIAL HIGHLIGHTS 2Q26 2,8 years CDI+1,00% AAA.br stable 4Q23 3,5 years CDI+1,41% AA+.br positive Term: Cost: Moody’s:
Page 24
Contra Capa 1 FOTOGRAFIA DA OPERAÇÃO . Alterar no Mestre https://ir.fleury.com.br/ ri@grupofleury.com.br Investor Relations https://ir.fleury.com.br/ ri@grupofleury.com.br +55 (11) 5014-7236 Fleury (Campinas - SP)
Page 25
Contra Capa 2 FOTOGRAFIA DA OPERAÇÃO Colocar sobre este quadrado Processing Facility (Vespasiano – MG)